- In April 2023, Sun Pharmaceutical Industries Ltd. announced an expansion of its dermatology pipeline with a strategic initiative targeting psoriasis treatment in Sub-Saharan Africa. The initiative leverages Sun Pharma's Acitretin-based formulations to enhance access to cost-effective therapies in regions with limited dermatological care. This move reinforces the company's global commitment to improving skin health in underserved populations while expanding its geographic footprint in the Acitretin market
- In March 2023, Teva Pharmaceuticals USA, Inc. launched a new generic Acitretin formulation in the U.S. market to increase affordability and accessibility for patients with chronic plaque psoriasis. The product launch aligns with Teva’s strategy to expand its generics portfolio and meet rising demand for effective oral systemic treatments in dermatology
- In March 2023, Merck KGaA announced a collaborative research initiative with leading European academic institutions to explore extended-release formulations of Acitretin for rare skin disorders such as Darier Disease and Pityriasis Rubra Pilaris (PRP). The partnership aims to address unmet clinical needs and enhance patient compliance through improved dosing regimens
- In February 2023, AvKARE, LLC received FDA approval for its Acitretin 25 mg capsules, which are now available across major hospital pharmacy chains and online distribution platforms. This marks a significant step in increasing the availability of cost-competitive Acitretin options in the U.S., particularly in rural and community health settings
- In January 2023, Glopec International Inc. entered into a strategic distribution agreement with pharmaceutical partners in Southeast Asia to supply Acitretin across public and private sector hospitals. The partnership is expected to boost market penetration in emerging markets such as Vietnam, Indonesia, and the Philippines, where the prevalence of dermatological conditions is rising
